Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan
{{output}}
Introduction: Diagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (EGFR, ALK, ROS1, BRAF, programmed cell death-ligand 1 [PD-L1]) was approved... ...
